Pharmaceutical Intellectual Property and Competition Law Review

COVID-19 has put a significant focus on the pharmaceutical industry in the development of treatments and a vaccine. Because the pharmaceutical business is a global industry, legal frameworks vary from region to region, especially in the area of intellectual property. The Pharmaceutical Intellectual Property and Competition Law Review examines the complexities of the industry in multiple jurisdictions providing a useful tool for managing global risks.

Norton Rose Fulbright Canada contributed to this publication, providing an overview of the intellectual property laws in Canada and how they interact with Canada’s competition law.